Menu
Recruiting NCT06796569

Systemic Immune Inflammatory Index in Systemic Lupus Erythematosus

— Observational Systemic Lupus Erythematosus Lupus Nephritis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: systemic immune inflammatory index.
Who it may be relevant to
Registry conditions: Systemic Lupus Erythematosus, Lupus Nephritis. Basic parameters: from 16 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Association of Systemic Immune Inflammatory Index with Disease Activity and Lupus Nephritis in Patients with Systemic Lupus Erythematosus

Overview

This study aims to investigate the association between the systemic immune-inflammation index and disease activity, as well as lupus nephritis in patients with systemic lupus erythematosus

Interventions

  • Diagnostic test systemic immune inflammatory index
    Systemic immune inflammatory index (SII) is a combination of three hematological parameters (platelets, neutrophils, and lymphocytes) and it is calculated using the following formula: SII = (neutrophil count × platelet count)/lymphocyte count.

Primary outcome measures

  • association of systemic immune-inflammation index (SII) disease activity in systemic lupus erythematosus [Time frame: baseline]
  • association of systemic immune-inflammation index (SII) and lupus nephritis in patients with systemic lupus erythematosus [Time frame: baseline]

Eligibility criteria

Inclusion criteria

  • o Older than 16 years
  • In a patient with SLE, patients who fulfill the criteria of the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR).
  • In patients with LN, patients whose diagnosis is confirmed by kidney biopsy and pathohistological verification (WHO classification, and the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification.

Exclusion criteria

  • Patients with other autoimmune rheumatological diseases, lymphoproliferative disorders, malignancies, liver diseases, end-stage kidney disease, diabetic nephropathy, active infections, recent history of blood transfusion and patients with deficiencies in vitamin B12, folate, and iron are excluded from the study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Case-control

Study locations

Egypt · 1 center
  • Sohag Faculty — Sohag

Identifiers

NCT: NCT06796569 · soh-Med-25-1-2MD

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗